Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
复制标题
DOI：
10.1038/nm.2311
复制
发表时间：
2011-03-01
期刊：
影响因子：
82.9
通讯作者：
Bernards, Rene
中科院分区：
文献类型：
--
作者：
Majewski, Ian J.;Bernards, Rene
从细胞毒性药物逐渐转变为高度选择性的靶向治疗癌症的药物，需要在分子水平上对癌症进行表征，以指导个体患者的治疗选择。在这里，我们回顾了可用于开发这些药物反应指标或生物标志物的基因组技术。我们还讨论了生物标志物在临床实践中发展和实施的障碍。
The gradual shift from cytotoxic drugs to highly selective, targeted therapeutic agents for cancer requires a parallel effort to characterize cancers at the molecular level to guide the choice of therapy for the individual patient. Here we review the genomic technologies that can be used to develop these drug response indicators, or biomarkers. We also discuss hurdles in their development and the implementation of biomarkers in clinical practice.